Yeh et al. BMC Cancer 2011, 11:139 http://www.biomedcentral.com/1471-2407/11/139 References 1. Stuart KA, Riordan SM, Lidder S, Crostella L, Williams R, Skouteris GG: Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int J Exp Pathol 2000, 81(1):17-30. 2. Li B, Kanamaru H, Noriki S, Fukuda M, Okada K: Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 1998, 5(5):436-440. 3. Peschard P, Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007, 26(9):1276-1285. 4. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001, 153(5):1023-1034. 5. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D, Chow NH: Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002, 20(6):1544-1550. 6. Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005, 92(10):1906-1914. 7. Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H: Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol 2009, 40(4):496-504. 8. Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1(7):493-502. 9. Dussault I, Bellon SF: From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2009, 9(2):221-229. 10. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R: A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007, 67(8):3529-3534. 11. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 1995, 80(2):213-223. 12. Chen Q, Seol DW, Carr B, Zarnegar R: Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997, 26(1):59-66. 13. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001, 7(7):1957-1962. 14. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003, 288(2):382-389. 15. Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR, Ho CL, Chow NH: Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol 2006, 176(5):2262-2267. 16. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC: Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000, 275(12):8806-8811. 17. Chow NH, Trink B, Eisenberger C, Sidransky D: Tyrosine kinase profile of bladder cancer. J Urol 1998, 159:1096. 18. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC: Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002, 8(2):361-367. 19. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC: Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 2002, 22(2B):1071-1078. 20. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW: Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003, 22(8):533-540. 21. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW: Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005, 7(12):1058-1064. 22. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005, 204(1):36-44. 23. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F: Overexpression of platelet-derived growth factor receptor alpha in breast cancer is Page 11 of 12 associated with tumour progression. Breast Cancer Res 2005, 7(5): R788-795. 24. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998, 71(1):29-37. 25. Fudge K, Bostwick DG, Stearns ME: Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996, 29(5):282-286. 26. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP: Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007, 6(7):1932-1941. 27. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J: Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 2007, 131(2):261-267. 28. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM: Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008, 3(9):963-970. 29. Lin YS, Su LJ, Yu CT, Wong FH, Yeh HH, Chen SL, Wu JC, Lin WJ, Shiue YL, Liu HS, et al: Gene expression profiles of the aurora family kinases. Gene Expr 2006, 13(1):15-26. 30. Chang TY, Wen YY, Yeh HH, Wang ST, Su IJ, Liu HS: Plasmid harboring lac repressor and tTA activator genes can regulate two inducible genes in mammalian cells. Biotechniques 1999, 27(3):466-469. 31. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000, 19(49):5548-5557. 32. Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, Usary J, Karaca M, Wong WK, Aprelikova O, Fero M, et al: Universal Reference RNA as a standard for microarray experiments. BMC Genomics 2004, 5(1):20. 33. Ben-Dor A, Shamir R, Yakhini Z: CAST - Clustering Affinity Search Technique. J Comput Biol 1999, 6:281-297. 34. Eble JNSG, Epstein JI, Sesterhenn IA, (Eds): Multilocular cystic renal cell carcinoma In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, 26. 35. Chen CC, Shieh B, Jin YT, Liau YE, Huang CH, Liou JT, Wu LW, Huang W, Young KC, Lai MD, et al: Microarray profiling of gene expression patterns in bladder tumor cells treated with genistein. J Biomed Sci 2001, 8(2):214-222. 36. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E: Ligand- independent activation of c-Met by fibronectin and alpha(5)beta(1)- integrin regulates ovarian cancer invasion and metastasis. Oncogene 2010, 30(13):1566-1576. 37. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2010, 30(12):1436-1448. 38. He L, Zhang J, Jiang L, Jin C, Zhao Y, Yang G, Jia L: Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog 2010, 49(10):882-891. 39. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, et al: A crucial function of PDGF in TGF-beta- mediated cancer progression of hepatocytes. Oncogene 2006, 25(22):3170-3185. 40. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, et al: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14(5):1478-1486. 41. Mudduluru G, Allgayer H: The human receptor tyrosine kinase Axl gene– promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 2008, 28(3):161-176. 42. Bonello MR, Khachigian LM: Fibroblast growth factor-2 represses platelet- derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. J Biol Chem 2004, 279(4):2377-2382. 43. Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T: Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 1995, 30(2):224-232.